GE HealthCare Technologies Temettü

Temettü kriter kontrolleri 0/6

GE HealthCare Technologies şu anki getirisi 0.14% olan temettü ödeyen bir şirkettir. Bir sonraki ödeme tarihi olan 15th November, 2024 temettüden önceki tarihi 18th October, 2024 dir.

Anahtar bilgiler

0.1%

Temettü verimi

Ödeme oranı

Sektör ortalama getirisi	2.0%
Bir sonraki temettü ödeme tarihi	15 Nov 24
Eski temettü tarihi	18 Oct 24
Hisse başına temettü	€0.108
Hisse başına kazanç	€3.47
Gelecekteki Temettü Verimi	0.2%

Son temettü güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: L0T German piyasası için dikkate değer bir temettü ödemesi yapmıyor, bu nedenle ödemelerin istikrarlı olup olmadığını kontrol etmeye gerek yok.

Büyüyen Temettü: L0T German piyasası için dikkate değer bir temettü ödemiyor, bu nedenle ödemelerin artıp artmadığını kontrol etmeye gerek yok.

Piyasaya Karşı Temettü Getirisi

GE HealthCare Technologies Piyasaya Karşı Temettü Getirisi

L0T temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (L0T)	0.1%
Pazarın Alt %25'i (DE)	1.6%
Pazarın En İyi %25'i (DE)	4.8%
Sektör Ortalaması (Medical Equipment)	2.0%
Analist tahmini (L0T) (3 yıla kadar)	0.2%

Önemli Temettü: L0T şirketinin temettüsü ( 0.14% ), German pazarındaki temettü ödeyenlerin en alttaki %25'ine ( 1.61% ) kıyasla dikkate değer değil.

Yüksek Temettü: L0T 'in temettüsü ( 0.14% ), German piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.76% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: L0T German piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: L0T German piyasası için dikkate değer bir temettü ödemiyor.

GE HealthCare Technologies Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Upcoming dividend of US$0.03 per share

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of 2024, Payable on August 15, 2024

Upcoming dividend of US$0.03 per share

Upcoming dividend of US$0.03 per share at 0.2% yield

Recent updates

GE HealthCare Technologies Inc. Announces Hospital Pulse, the Newest Tile for Its Command Center Software Platform

GE HealthCare Introduces Easy-To-Use, Easy-To-Learn, Easy-To-Appoint Versana Premier Multi-Purpose Ultrasound System

Upcoming dividend of US$0.03 per share

GE Healthcare Accelerates Artificial Intelligence Adoption with New Offering to Advance Enterprise Imaging

GE HealthCare Technologies Inc. to Report Q3, 2024 Results on Oct 30, 2024

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

GE Healthcare Announces FDA Approval of Flyrcado (Flurpiridaz F 18) Injection Pet Radiotracer for Enhanced Diagnosis of Coronary Artery Disease

Second quarter dividend of US$0.03 announced

GE HealthCare Introduces Elevated Venue Point of Care Ultrasound Solutions and New Tablet-Based Venue Sprint

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

GE HealthCare Technologies Inc. Showcases Latest AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments At the Point of Care At ESC 2024

GE HealthCare Announces the Publication of the MASTER Trial Results in the Peer-Reviewed Journal Anesthesia and Analgesia

Insider recently sold €1.4m worth of stock

Second quarter 2024 earnings released: EPS: US$0.94 (vs US$0.92 in 2Q 2023)

GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q2, 2024 Results on Jul 31, 2024

First quarter dividend of US$0.03 announced

GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of 2024, Payable on August 15, 2024

GE Healthcare Names Adam Holton as Chief People Officer

GE HealthCare Unveils SIGNA MAGNUS, an FDA 510(K) Pending Head-Only Magnetic Resonance (MR) Scanner Designed to Explore Advance Advancements in Neuro Science

GE HealthCare Launches New Era of AI-Enhanced, Personalized Oncology Solutions at ESTRO 2024 Congress

First quarter 2024 earnings released: EPS: US$0.82 (vs US$0.41 in 1Q 2023)

GE HealthCare Technologies Inc. Reaffirms Earnings Guidance for the Full Year 2024

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women's Health Imaging

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q1, 2024 Results on Apr 30, 2024

GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024

GE Healthcare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

GE HealthCare Technologies Inc. to Feature Latest Technologies in Interventional Radiology Focused on Precision Care At Sir 2024

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

Now 23% overvalued after recent price rise

GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $1.06925 billion.

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

New minor risk - Profit margin trend

Full year 2023 earnings released

Now 29% overvalued after recent price rise

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Full Year of 2024

GE HealthCare Technologies Inc. Receives 510(K) Clearance from the United States Food and Drug Administration for Novii™+ Wireless Patch Solution

GE HealthCare Technologies Inc. Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation

Now 20% overvalued after recent price rise

GE HealthCare Technologies Inc. to Report Q4, 2023 Results on Feb 06, 2024

GE HealthCare Technologies Inc. (NasdaqGS:GEHC) entered into definitive agreement to acquire MIM Software Inc.

Upcoming dividend of US$0.03 per share at 0.2% yield

GE HealthCare Highlights Commitment to Delivering Better Patient Experiences and Outcomes Through Deep Learning at RSNA 2023

GE HealthCare Expands On-Device Triage Capabilities of Critical Care Suite with FDA Clearance of Algorithm for Pneumothorax Detection, Notification, Triage and Diagnosis

GE HealthCare Technologies Inc. Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection

GE Healthcare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released

GE HealthCare Technologies Inc. Announces to Showcase Some of the Latest Innovations Designed to Help Clinicians in the Treatment of Cardiovascular Disease At the 2023 Transcatheter Cardiovascular Therapeutics Conference

GE HealthCare Technologies Inc. to Report Q3, 2023 Results on Oct 31, 2023

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

GE HealthCare Launches Enhanced Venue Family Ultrasound Systems Featuring AI-Driven Caption Guidance

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin